Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;7(9):4371-4378.
doi: 10.1002/cam4.1705. Epub 2018 Jul 31.

Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting

Sarah S Mougalian  1 , Ronda Copher  2 , Jonathan K Kish  3 , Lindsay McAllister  3 , Zhixiao Wang  2 , Mary Broscious  3 , David Garofalo  3 , Janna Radtchenko  3 , Bruce A Feinberg  3
Affiliations

Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting

Sarah S Mougalian et al. Cancer Med. 2018 Sep.

Abstract

Introduction: Real-world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple-negative breast cancer (mTNBC) patients treated with eribulin mesylate at community oncology practices in the United States.

Methods: Physicians identified mTNBC patients initiating eribulin between 1 January 2011 and 1 January 2014 and abstracted data into an electronic case report form (eCRF). Eribulin treatment in the metastatic setting was categorized as early use (EU, first-/second-line) and late use (LU, third-line or later). Patient characteristics, overall survival (OS), disease response (per treating physician), and adverse events (AEs) rates in each group, respectively, are reported.

Results: Overall 252 eCRFs were completed: 125 (49.6%) EU and 127 (50.4%) LU. The median age at metastatic diagnosis was 53 years and 42.1% were stage IV at their initial diagnosis. The median duration of follow-up from the initiation of first-line treatment was 24 months. Rates of disease response (complete or partial per treating physician) were 69.9% in the EU group and 48.8% in the LU group. The five most commonly reported adverse events during eribulin were as follows: fatigue (65.1%), weakness (40.1%), decreased appetite (32.5%), neutropenia (31.0%), and leukopenia (27.4%). Discontinuation of eribulin due to AE was observed in 4.0% of patients. Median OS from initiation of eribulin was 23.0 months (95% CI: 18.7-27.3) among EU and 14.7 (95% CI: 12.6-16.9) among LU.

Conclusion: In the real-world eribulin-treated mTNBC, patients have more sites of metastatic disease and exposure to greater numbers of prior therapies compared to RCTs. The median OS of 14.7 months among LU patients is consistent with, and slightly longer than the 13.1 months and 14.4 months reported in the EMBRACE and Study 301 clinical trials, respectively.

Keywords: eribulin; metastatic breast cancer; real-world; survival; triple negative.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival from initiation of eribulin stratified by early (LOT 1/2) vs late (LOT 3+) use of eribulin. Median OS EU : 23.0 mo (95% CI: 18.7‐27.3). Median OS LU: 14.7 mo (95% CI: 12.6‐16.9)
See this image and copyright information in PMC

References

    1. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype. Cancer. 2007;109(9):1721‐1728. - PubMed
    1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869‐10874. - PMC - PubMed
    1. Szelekly B, Silber AL, Pusztai L. New therapeutic strategies for triple‐negative breast cancer. Oncology. 2017;31(2):130‐137. - PubMed
    1. Isakoff SJ, Mayer EL, He L, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple‐negative breast cancer. J Clin Oncol. 2015;33(17):1902‐1909. - PMC - PubMed
    1. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple‐negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29‐33. - PubMed

Publication types

MeSH terms